Respiri Limited

CHIA:RSH Stock Report

Market Cap: AU$108.4m

Respiri Management

Management criteria checks 1/4

Respiri's CEO is Marjan Mikel, appointed in Dec 2019, has a tenure of 4.92 years. total yearly compensation is A$758.38K, comprised of 56.5% salary and 43.5% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth A$382.93K. The average tenure of the management team and the board of directors is 3.4 years and 1.8 years respectively.

Key information

Marjan Mikel

Chief executive officer

AU$758.4k

Total compensation

CEO salary percentage56.5%
CEO tenure4.9yrs
CEO ownership0.4%
Management average tenure3.4yrs
Board average tenure1.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Marjan Mikel's remuneration changed compared to Respiri's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$758kAU$428k

-AU$7m

Mar 31 2024n/an/a

-AU$7m

Dec 31 2023n/an/a

-AU$6m

Sep 30 2023n/an/a

-AU$6m

Jun 30 2023AU$570kAU$428k

-AU$6m

Mar 31 2023n/an/a

-AU$6m

Dec 31 2022n/an/a

-AU$6m

Sep 30 2022n/an/a

-AU$6m

Jun 30 2022AU$607kAU$428k

-AU$7m

Mar 31 2022n/an/a

-AU$7m

Dec 31 2021n/an/a

-AU$8m

Sep 30 2021n/an/a

-AU$9m

Jun 30 2021AU$2mAU$428k

-AU$11m

Mar 31 2021n/an/a

-AU$12m

Dec 31 2020n/an/a

-AU$12m

Sep 30 2020n/an/a

-AU$10m

Jun 30 2020AU$2mAU$187k

-AU$7m

Compensation vs Market: Marjan's total compensation ($USD497.20K) is above average for companies of similar size in the Australian market ($USD302.43K).

Compensation vs Earnings: Marjan's compensation has increased whilst the company is unprofitable.

CEO

Marjan Mikel

4.9yrs

Tenure

AU$758,383

Compensation

Mr. Marjan Mikel, M.Com, BSc (Hons), Dip Ed, MAICD), serves as Chief Executive Officer and Managing Director at Respiri Limited since December 2, 2019 and serves as its Executive Director since November 25...

Leadership Team

NamePositionTenureCompensationOwnership
Nicholas Smedley
Executive Chairman5.1yrsAU$487.75k1.26%
A$ 1.4m
Marjan Mikel
CEO, MD & Executive Director4.9yrsAU$758.38k0.35%
A$ 382.9k
Peter Hildebrandt
Chief Operations Officer4yrsAU$276.55kno data
George Vlachodimitropoulos
Chief Technology Officer3.3yrsAU$284.75kno data
Samaneh Shirazi
Chief Research Officer5.8yrsAU$208.01kno data
Theo Antonopoulos
Chief Commercial Officer3.4yrsAU$302.66kno data
William Sigsbee
Head of US Operations & Chief Commercial Officer for the US market1.6yrsno datano data
Justin Mouchacca
Joint Company Secretaryless than a yearno datano data
Nova Taylor
Joint Company Secretaryless than a yearno datano data
Noam Gavriely
Medical & Scientific Advisorno dataAU$310.61kno data
Simon Godfrey
Medical & Scientific Advisorno datano datano data

3.4yrs

Average Tenure

Experienced Management: RSH's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Nicholas Smedley
Executive Chairman5.1yrsAU$487.75k1.26%
A$ 1.4m
Marjan Mikel
CEO, MD & Executive Director5yrsAU$758.38k0.35%
A$ 382.9k
Gerard Criner
Member of Medical Advisory Board1.8yrsno datano data
William Krimsky
Chair of Medical Advisory Board1.8yrsno datano data
Bruce Thompson
Member of Medical & Scientific Advisory Boardno dataAU$1.47kno data
Stephen Selinger
Member of Medical Advisory Board1.8yrsno datano data
Jonathan Hovda
Member of Medical Advisory Board1.8yrsno datano data
Tom Takubo
Non-Executive Directorless than a yearno datano data

1.8yrs

Average Tenure

Experienced Board: RSH's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.